Processa Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 18, 2026

PCSA$1.95+1.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

December 31, 2025 · December 31, 2024
ASSETS
Current Assets
Cash and cash equivalents		$5,536,955	$1,191,325
Prepaid expenses and other		133,919	687,829
Total Current Assets		5,670,874	1,879,154
Digital assets at fair value		1,145,180	-
Prepaid expenses		993,701	1,274,442
Equipment, net		3,812	5,016
Operating lease right-of-use assets, net		-	70,677
Total Assets		$7,813,567	$3,229,289
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current maturities of lease liability	$	-	$73,020
Accounts payable		1,056,796	880,880
Accrued expenses		1,179,457	578,731
Total Current Liabilities		2,236,253	1,532,631
Non-current lease liability		-	487
Total Liabilities		2,236,253	1,533,118
Commitments and Contingencies		-	-
Stockholders’ Equity
Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2025 or 2024		-	-
Common stock, par value $0.0001, 1,000,000,000 shares authorized; 2,572,114 issued and 2,571,914 outstanding at December 31, 2025 and 148,308 issued and 148,108 outstanding at December 31, 2024		257	15
Additional paid-in capital		106,660,090	89,215,355
Treasury stock, 200 shares at cost		(300,000)	(300,000)
Accumulated deficit		(100,783,033)	(87,219,199)
Total Stockholders’ Equity		5,577,314	1,696,171
Total Liabilities and Stockholders’ Equity		$7,813,567	$3,229,289

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.